CME Heads Into Q2 Print With Options Turning Bullish

CME Group reports its Q2 results on June 9 against a backdrop of genuine tension: the stock has shed 10% over the past month to $257.40, yet options traders are the most bullish on the name they've been all year.

The options signal is the standout heading into the print. The put/call ratio has dropped to 0.99 — nearly two standard deviations below its 20-day average of 1.07, making it the lowest defensive reading in the past 52 weeks. That's a sharp reversal from early May, when the PCR ran above 1.20, and it points to a meaningful rotation toward calls even as the stock has weakened. Borrow conditions confirm there's no short-side pressure to speak of: availability is effectively unlimited, short interest is only 1.3% of the float and falling, and cost to borrow is a negligible 0.48%.

The bull and bear debate centres on volume trajectory and competitive pressure. Bulls point to the March-quarter revenue beat — total revenues up 8.1% year-over-year, led by 14.5% growth in Market Data — and CME's long track record of compounding average daily volume above 7% annually. The dividend track record, running unbroken for more than 14 years, reinforces the quality story. Bears argue that a rate-cutting cycle will structurally weaken interest rate futures volumes, the company's largest product line, and that FMX competition is capping near-term margin upside. Analyst consensus reflects the split: Morgan Stanley maintained Overweight but trimmed its target to $353, while JP Morgan's Underweight camp has a $266 target — well below the $305 mean. The stock at $257 already trades below JP Morgan's target, a gap the market is clearly pricing as a risk rather than an opportunity. EV/EBITDA has expanded modestly over the past 30 days, even as the P/E has compressed nearly three turns over the same period, suggesting the multiple contraction is real but not yet extreme.

The CEO's mid-May open-market sales — roughly $10.5 million across two transactions at prices around $298-$305 — add a note of caution, though the net 90-day insider position is modestly positive once awards are included. Among peers, CBOE fell 15% on the week and MKTX dropped 10%, suggesting broad sector pressure rather than a CME-specific story. ICE declined a more measured 4%, closer to CME's own weekly move.

The June 9 print will test whether CME's Market Data momentum and fee-per-contract pricing can offset any softness in rate futures volumes — and whether management's cost discipline is sufficient to defend margins against a more competitive landscape.